 March 09, 2026

Preliminary statistics from VCBeat tracked 11 financing events in China's healthcare sector between March 2 and 6, 2026 (excluding IPOs and private placements). The period was led by Deep Intelligent Pharma's USD 40 million round, followed by QL Biopharm's over RMB 500 million Series C round.

 March 10, 2026

In a crowded pharmaceutical digitalization landscape, why do leading pharmaceutical companies favor Akso exclusively? What competitive advantages enable it to lead the sector in compliance-focused digital intelligence and unlock new industry potential? The answer lies in its robust product strength, solid operational foundation, and precise understanding of industry demands.

 February 24, 2026

Independently developed by Sciwind Biosciences as a new-generation cAMP-biased GLP-1 receptor agonist, Ecnoglutide injection has demonstrated robust efficacy and a favorable safety profile across multiple clinical studies, owing to its unique biased mechanism. In Chinese patients, it achieved a placebo-adjusted mean weight loss of 15.1%, with 92.8% of patients attaining clinically meaningful weight loss, and over 80% of patients achieving glycemic targets (HbA1c < 7.0%).

 March 03, 2026

Candid's operator, Ken Song, is a serial entrepreneur in the U.S. biopharmaceutical sector. His previous company, RayzeBio, took only three years from its founding to being acquired by BMS for $4.1 billion. The core capabilities of Ken Song's team were summarized by Wu Chenbing, CEO of partner EpimAb Biotherapeutics, into three points: strong scientific judgment, rapid team assembly, and high capital cohesion ability.